Heat Biologics Files IND for Bladder Cancer Product Candidate

Appoints Dr. Melissa Price as Vice President, Clinical and Regulatory Affairs

Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, today announced that it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for its second product candidate, HS-410, which will be evaluated in bladder cancer. 

The Company also named Melissa Price, Ph.D., as Vice President, Clinical and Regulatory Affairs. Dr. Price will be responsible for the implementation of Heat's HS-410 bladder cancer program, as well as all of the Company's clinical studies. Dr. Price will also direct the company's regulatory strategy. 

Alcobra Ltd. Selects CNS Clinical Trials Expert Premier Research as CRO for Phase III Clinical Study of MG01CI as a Treatment for Adults With ADHD

Alcobra Ltd. (ADHD) (the "Company"), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, announced today that it has selected Premier Research as its Clinical Research Organization ("CRO") to conduct a Phase III clinical study of its proprietary drug MG01CI as a treatment for adults with Attention Deficit Hyperactivity Disorder (ADHD).

Neptune and Rimfrost Sign Krill Oil Manufacturing and Supply Agreement

Neptune Technologies & Bioressources Inc. ("Neptune") (NEPT) (NTB.TO) and Rimfrost USA, LLC ("Rimfrost") announce that they have signed a strategic non-exclusive krill oil Manufacturing and Supply Agreement giving Neptune the right to purchase, at a preferred price, up to 800 metric tons of krill oil during the first three-year term of the renewable agreement.

"Today's announcement, which is now in effect, is another important step in our action plan to secure and increase our krill oil supply chain through third party agreements," highlighted Mr. Henri Harland, President and CEO of Neptune. "By moving from a centralized to a diversified production model we are further strengthening and safeguarding Neptune's operations."

Fate Therapeutics, Inc. Announces Pricing of Initial Public Offering

Fate Therapeutics, Inc. (FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced the pricing of its initial public offering of 6,666,667 shares of its common stock price to the public of $6.00 per share, before underwriting discounts. The shares are scheduled to begin trading on The NASDAQ Global Market under the ticker symbol "FATE" on October 1, 2013. In addition, Fate has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of common stock at the same price. The offering is expected to close on October 4, 2013, subject to customary closing conditions.